PT-141 (10mg)
$49.99
PT-141 (Bremelanotide) is a synthetic cyclic peptide analogue derived from Melanotan 2, functioning as a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R receptors within the central nervous system. In research settings, PT-141 is studied for its hypothalamic signaling interactions and CNS melanocortin receptor pharmacology.
BioRhex supplies PT-141 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic peptide analogue derived from Melanotan 2, functioning as a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R receptors within the central nervous system. In research settings, PT-141 is studied for its hypothalamic signaling interactions and CNS melanocortin receptor pharmacology.
BioRhex supplies PT-141 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
PT-141 is a central melanocortin receptor agonist studied for its CNS signaling properties. Preclinical research models examine how PT-141 may influence:
• MC3R and MC4R receptor binding and activation in CNS tissue models
• Hypothalamic neuropeptide signaling pathway modulation
• Dopaminergic pathway interactions in preclinical research systems
• Autonomic nervous system pathway modeling in experimental environments
• Central melanocortin receptor pharmacology and signaling cascade dynamics
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of PT-141
PT-141 was identified as a metabolite and structural derivative of Melanotan 2 during melanocortin analogue research. Unlike MT-2, PT-141 was found to exert its primary receptor activity through central nervous system melanocortin receptor engagement.
Preclinical research demonstrated PT-141’s affinity for hypothalamic MC4R and associated downstream signaling pathways, establishing it as a useful tool in CNS neuropeptide receptor pharmacology research.
PT-141 continues to be studied in central melanocortin biology within controlled laboratory environments.
Molecular Structure
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Research Findings
Published and preclinical research on PT-141 covers several areas of scientific investigation, including:
CNS melanocortin receptor research: Studies examine PT-141’s binding affinity and activation profile at MC3R and MC4R in central nervous system tissue models.
Hypothalamic pathway modeling: Research investigates downstream signaling cascades following central melanocortin receptor activation in hypothalamic experimental systems.
Dopaminergic pathway research: Laboratory models explore PT-141’s interactions with dopamine pathway signaling in preclinical environments.
Neuropeptide pharmacology: Studies evaluate receptor occupancy kinetics and intracellular signaling cascade activation in controlled research systems.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
What type of research is PT-141 used for?
What type of research is PT-141 used for?
PT-141 is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.
Where is BioRhex’s PT-141 manufactured?
Where is BioRhex’s PT-141 manufactured?
All BioRhex compounds, including PT-141, are manufactured in a GMP-compliant facility located in the United States.
What testing does BioRhex conduct on PT-141?
What testing does BioRhex conduct on PT-141?
Every batch of PT-141 undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Is PT-141 approved for human use?
Is PT-141 approved for human use?
No. PT-141 is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Who should handle this compound?
Who should handle this compound?
Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. PT-141 is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
